Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 October 2009, Vol. 114, No. 14, pp. 2854-2855.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Doggen, C. J. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doggen, C. J. M.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

InsideBlood

CLINICAL TRIALS

Comment on Cushman et al, page 2878

High coagulant factors & venous thrombosis

Carine J. M. Doggen

UNIVERSITY OF TWENTE

In this issue of Blood, results from the Longitudinal Investigation of Thromboembolism (LITE)1 show that, of the coagulant factors IX through XIII, only elevated levels of procoagulant factor XI were associated with a first venous thrombosis. LITE is the first prospective cohort study reporting on all these factors. Factor IX initially appeared to be associated with thrombosis but, after adjustment for primarily body mass index, the association disappeared.

The annual incidence of venous thrombosis is 1 per 1000 persons and mortality among patients with pulmonary emboli is high. Patients may develop a postthrombotic syndrome and recurrent events occur frequently.2 Major risk factors for venous thrombosis consist of acquired and genetic factors. Hypofibrinolysis appears to be a risk factor, but the role of individual fibrinolytic proteins is still unclear.3 Hypercoagulability caused by an imbalance between anticoagulant and procoagulant systems increases the risk of venous thrombosis.4 Deficiencies of antithrombin, protein C, and protein S are strong but rare risk factors for venous thrombosis. Factor V Leiden and the prothrombin 20210A mutation are more prevalent with a moderate increase in risk. High levels of factor VIII clearly increase the risk of venous thrombosis, but the results of studies investigating the effects of prothrombin, factor V, factor VII, and fibrinogen are inconsistent.5 In studies in which associations between these latter factors and venous thrombosis were found, the effects were much less than those of elevated factor VIII.4

So far, the effects of coagulant factors IX through XIII have been investigated in only a few case-control studies, including the Leiden Thrombophilia Study (LETS)5 and, more recently, the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) study.6,7 Prospective cohort studies have been lacking so far.5

In this issue of Blood, an efficient nested case-control design has been used within LITE, a prospective cohort study in individuals aged 45 to 100 years, with a median follow-up period of more than 9 years.1 Included in the analyses were 462 validated cases of venous thrombosis and 1047 controls. Coagulation measurements took place in blood samples collected mostly at baseline. Levels were therefore measured long before the event, as opposed to case-control studies, in which levels are measured after the event, thus ruling out the possibility of reverse causation. A disadvantage is that levels may not reflect the situation immediately before the event, which, from an etiological point of view, would be the ideal situation. However, this is difficult if not impossible to achieve in any study design.

Although one might be inclined to expect differences in results between case-control studies and this cohort study simply because different populations were included or different assays used, the results were quite similar. Levels of factor X, factor XII, and factor XIII were not associated with risk of venous thrombosis.1,5,8 Elevated factor XI was associated with a nearly 2-fold increased risk for the top quintile or percentile, which is quite close to the risk of factor VIII.1,5,7 High levels of factor IX were associated with an increased risk of venous thrombosis in all studies,1,5,6,9 but after adjustment for body mass index (BMI), the risk in LITE attenuated to the null.1 No adjustments for BMI were performed in the case-control studies.5,6,9

For some coagulation factors, the associated risk is stronger for deep vein thrombosis in the leg than for a pulmonary embolism. The opposite may be true for elevated factor XI in LITE, as the risk of pulmonary embolism combined with deep vein thrombosis appears to be larger than for deep vein thrombosis alone. However, the case classification in this study may not be reliable, preventing strong conclusions.

If these overall results are confirmed by other studies, further study into possible mechanisms for the increased risk of elevated levels of factor XI is warranted, which include increased fibrin formation and decreased fibrinolysis.10 Furthermore, this study raises the question whether elevated factor XI is also a risk factor for a recurrent venous thrombotic event, and if so, whether treatment prevents recurrent events. Until these results become available, measurement in clinical practice is not yet indicated.

Footnotes

Conflict-of-interest disclosure: The author declares no competing financial interests. {blacksquare}

REFERENCES

  1. Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood. 2009;114(14):2878–2883.[Abstract/Free Full Text]

  2. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007;44(2):62–69.[CrossRef][Medline] [Order article via Infotrieve]

  3. Meltzer ME, Doggen CJM, de Groot PG, Rosendaal FR, Lisman T. Fibrinolysis and the risk of venous and arterial thrombosis. Curr Opin Hematol. 2007;14(3):242–248.[CrossRef][Medline] [Order article via Infotrieve]

  4. Bertina RM. The role of procoagulants and anticoagulants in the development of venous thromboembolism. Thromb Res. 2009;123(suppl 4):S41–S45.

  5. Nossent AY, Eikenboom JCJ, Bertina RM. Plasma coagulation factor levels in venous thrombosis. Semin Hematol. 2007;44(2):77–84.[CrossRef][Medline] [Order article via Infotrieve]

  6. Bezemer ID, Arellano AR, Tong C, et al. F9 Malmö, factor IX and deep vein thrombosis. Haematologica. 2009;94(5):693–699.[Abstract/Free Full Text]

  7. Bezemer ID, Bare LA, Doggen CJM, et al. Gene variants associated with deep vein thrombosis. JAMA. 2008;299(11):1306–1314.[Abstract/Free Full Text]

  8. Van Kanel R, Wuillemin WA, Furlan M, Lammle B. Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis. 1992;3(5):555–561.[Medline] [Order article via Infotrieve]

  9. Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years: relationships to hormone replacement therapy. Thromb Haemost. 2000;83(4):530–535.[Medline] [Order article via Infotrieve]

  10. von dem Borne PA, Cox LM, Bouma BM. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor. Blood Coagul Fibrinolysis. 2006;17(4):251–257.[CrossRef][Medline] [Order article via Infotrieve]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology
Mary Cushman, Ellen S. O'Meara, Aaron R. Folsom, and Susan R. Heckbert
Blood 2009 114: 2878-2883. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Doggen, C. J. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doggen, C. J. M.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020